Taysha Gene Therapies, Inc. TSHA Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | -1,130.6%-33.1pp | -1,097.6%-629pp | -468.8%+6,024pp | -6,492.7%— | |
| Net margin | -1,115.3%-43.6pp | -1,071.6%— | —— | -6,635.3%— | |
| Returns | |||||
| Return on equity | -68.5%+53.5pp | -121.9%— | —— | -344.7%-244pp | |
| Efficiency | |||||
| Asset turnover | 0×0.0× | 0.1×-0.1× | 0.1×+0.1× | 0×— | |
| Liquidity | |||||
| Current ratio | 12.2×+6.8× | 5.4×+1.3× | 4.1×+2.5× | 1.5×-1.5× | |
| Leverage | |||||
| Debt-to-equity | 0.3×-0.6× | 0.9×+0.1× | 0.8×-63.5× | 64.3×+64.0× | |
| Per Share | |||||
| Book value per share | $0.77+170% | $0.29-55.7% | $0.65+2,888% | $0.02-99.1% | |
| Valuation | |||||
| Market capitalization | $1.51B+325% | $354.55M+23.0% | $288.17M+160% | $110.97M-71.3% | |
| Price / sales | 154.2×+112× | 42.5×+23.9× | 18.7×-25.7× | 44.4×— | |
| Price / book | 6.1×+1.1× | 5×+1.1× | 3.8×-113× | 116.9×+113× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Taysha Gene Therapies, Inc.'s ratios come from?
- Every ratio is computed from Taysha Gene Therapies, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
